Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Phosphate

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    806 result(s) found for: Phosphate. Displaying page 1 of 41.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2022-000258-27 Sponsor Protocol Number: V116-003 Start Date*: 2022-08-01
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults
    Medical condition: Pneumococcal infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10035644 Pneumococcal infection NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2011-005102-30 Sponsor Protocol Number: OVG2011/05 Start Date*: 2011-12-08
    Sponsor Name:University of Oxford
    Full Title: A phase III randomised, open label clinical trial evaluating the immunogenicity of a 10-valent pneumococcal conjugate vaccine booster compared to the standard 13-valent pneumococcal conjugate vacci...
    Medical condition: The study will include healthy children who have already been vaccinated with 2 doses of Prevenar 13 according to the UK routine immunisation schedule at 2 and 4 months of age. Both vaccines used i...
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-004730-25 Sponsor Protocol Number: ACT 402 Start Date*: 2009-05-27
    Sponsor Name:INEOS Healthcare Limited
    Full Title: An open, randomised, controlled, parallel group, Phase III study to investigate the safety and efficacy of fermagate and sevelamer hydrochloride in haemodialysis patients with hyperphosphataemia.
    Medical condition: Hyperphosphataemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020711 Hyperphosphataemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) IT (Prematurely Ended) BE (Completed) GB (Prematurely Ended) HU (Prematurely Ended) EE (Prematurely Ended) LT (Completed) BG (Prematurely Ended) SK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-004729-41 Sponsor Protocol Number: ACT 401 Start Date*: 2009-10-27
    Sponsor Name:INEOS Healthcare Limited
    Full Title: An open, randomized, controlled, parallel group, Phase III study to investigate the safety and efficacy of fermagate and lanthanum carbonate together with a randomized placebo controlled double bli...
    Medical condition: Hyperphosphatemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020712 Hyperphosphatemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Ongoing) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-003698-24 Sponsor Protocol Number: 71254 Start Date*: 2021-09-20
    Sponsor Name:Amsterdam UMC, location VUmc
    Full Title: Patient preference-based phosphate binder therapy in haemodialysis patients: a feasibility study on patient satisfaction
    Medical condition: Chronic kidney disease, End-stage renal disease
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004857 10076412 Chronic kidney disease stage 5 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-005746-39 Sponsor Protocol Number: IH 001 (ACT 2) Start Date*: 2006-02-21
    Sponsor Name:Ineos Healthcare Ltd
    Full Title: A multicentre Phase II study with Alpharen™: an open-label, dose-ranging phase followed by a placebo-controlled, double-blind, parallel-group comparison in haemodialysis subjects with hyperphosphat...
    Medical condition: Hyperphosphataemia in haemodialysis subjects
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-000488-95 Sponsor Protocol Number: 6520-9961-04 Start Date*: 2013-08-28
    Sponsor Name:MEDICE Arzneimittel Pütter GmbH & Co. KG
    Full Title: Efficacy and tolerability of nicotinamide as add-on therapy compared to placebo in dialysis-dependent patients with hyperphosphatemia
    Medical condition: Dialysis-dependent patients with hyperphosphatemia
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004861 10020712 Hyperphosphatemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PL (Completed) AT (Completed) HU (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-004319-33 Sponsor Protocol Number: D5613C00001 Start Date*: 2014-04-28
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase 2b, Randomized, Double blind, Placebo-controlled, Parallel group, Multicentre Dose finding Study to evaluate the Efficacy, Safety and Tolerability of AZD1722 to Treat Hyperphosphatemia in E...
    Medical condition: Hyperphosphatemia in patients with end-stage renal disease on hemodialysis.
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004861 10020712 Hyperphosphatemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-003565-40 Sponsor Protocol Number: PA-CL-03 Start Date*: 2007-12-18
    Sponsor Name:Vifor (International) Inc.
    Full Title: An open-label randomized Phase II study of PA21 compared to sevelamer to evaluate the ability of PA21 to control serum phosphate levels and the tolerability in patients with chronic kidney disease ...
    Medical condition: patients with chronic kidney disease undergoing hemodialysis hyperphosphatemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020712 Hyperphosphatemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) SE (Completed) GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-000953-38 Sponsor Protocol Number: MK-1986-014 Start Date*: 2018-02-07
    Sponsor Name:Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc.
    Full Title: A Phase 1, Single-and Multiple-Dose Safety and Pharmacokinetic Study of Oral and IV Tedizolid Phosphate (MK-1986) in Inpatients Under 2 Years Old
    Medical condition: Treatment or prophylaxis against Gram-positive infections
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10052891 Skin bacterial infection PT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: BG (Completed) GB (GB - no longer in EU/EEA) NO (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-003268-37 Sponsor Protocol Number: 205239 Start Date*: 2018-09-26
    Sponsor Name:GlaxoSmithKline Biologicals SA
    Full Title: A Phase IIIB, Observer-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Assess the Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine when...
    Medical condition: Healthy subjects (to assess the safety and immunogenicity of Bexsero and Prevnar13 when administered concomitantly with RIV to healthy infants).
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2014-004023-40 Sponsor Protocol Number: TR701-122 Start Date*: 2015-05-06
    Sponsor Name:Cubist Pharmaceuticals, Inc.
    Full Title: PHASE 3 STUDY OF IV TO ORAL 6-DAY TEDIZOLID PHOSPHATE COMPARED WITH 10-DAY COMPARATOR IN SUBJECTS 12 TO <18 YEARS WITH cSSTI
    Medical condition: complicated skin and soft tissue infection (cSSTI)
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004862 10040786 Skin structures and soft tissue infections HLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SI (Completed) BG (Completed) DE (Prematurely Ended) CZ (Completed) LT (Completed) LV (Completed) ES (Completed) PL (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2005-004316-73 Sponsor Protocol Number: 3189 Start Date*: 2006-08-23
    Sponsor Name:Royal Liverpool University hospital
    Full Title: The effects of growth hormone, strontium ranelate and phosphate on PTH circadian rhythm, PTH target organ sensitivity, bone turnover markers, phospho-calcium metabolism and bone mineral density. A ...
    Medical condition: Osteoporosis and Reduced Bone mineral density (T scores< -1.0 on DEXA scan), Adult growth hormone deficiency ( GH levels,9mU/l on Insulin stress test) with reduced BMD (T scores< -1.0 on DEXA scan)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-004748-36 Sponsor Protocol Number: PA-CL-03A Start Date*: 2008-10-30
    Sponsor Name:Vifor (International) Inc.
    Full Title: An open-label, randomized, active controlled multi center phase II dose finding study to evaluate the ability of PA21 to lower serum phosphate levels and the tolerability in patients with chronic k...
    Medical condition: Hyperphosphatemia in patients with chronic kidney disease on maintenance hemodialysis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020712 Hyperphosphatemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2013-002373-22 Sponsor Protocol Number: 2012-NIGRAM-VUMC-001 Start Date*: 2014-05-12
    Sponsor Name:Vrije Universiteit Medical Center
    Full Title: ThE SoF-Trial (SoFT) - The Effect of Sevelamer on FGF23 Trial - A clinical trial assessing the quantitative effect of phosphate binding therapy on FGF23.
    Medical condition: cardiovascular disease in chronic kidney disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-000136-27 Sponsor Protocol Number: CCD02 Start Date*: 2008-03-17
    Sponsor Name:Cytonet GmbH & Co KG
    Full Title: Open, Prospective, Uncontrolled, Multicentre Study to Evaluate The Safety and Efficacy of Multiple Applications of Liver Cell Suspension Into The Portal Vein in Children with Urea Cycle Disorders (...
    Medical condition: Neonates and Infants up to 3 months including with prenatally or postnatally confirmed urea cycle disorder with below listed deficiency and children aged > 3 months up to 5 years including with con...
    Disease: Version SOC Term Classification Code Term Level
    18.1 10010331 - Congenital, familial and genetic disorders 10052450 Ornithine transcarbamoylase deficiency PT
    18.1 10010331 - Congenital, familial and genetic disorders 10058298 Argininosuccinate synthetase deficiency PT
    18.1 10010331 - Congenital, familial and genetic disorders 10058297 Carbamoyl phosphate synthetase deficiency PT
    Population Age: Newborns, Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-004178-24 Sponsor Protocol Number: RP-OSV-02-D Start Date*: 2013-12-27
    Sponsor Name:Fresenius Medical Care Deutschland GmbH
    Full Title: Study to investigate the therapeutic equivalence of OsvaRen® tablets and OsvaRen® granules
    Medical condition: Hyperphosphataemia in end stage renal failure patients on extracorporeal renal replacement therapy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-002602-39 Sponsor Protocol Number: 1562016 Start Date*: 2016-10-25
    Sponsor Name:Radboud University Medical Center
    Full Title: FGF23 response in hypophosphatemia
    Medical condition: healthy volunteers the information of this pilot study will be used in the care of patients with hypophosphatemia due to renal phosphate wasting
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-004595-29 Sponsor Protocol Number: TR701-120/MK-1986-013 Start Date*: 2016-01-08
    Sponsor Name:Cubist Pharmaceuticals, LLC
    Full Title: A Phase 1, Single-Administration Pharmacokinetic and Safety Study of Oral and IV Tedizolid Phosphate in Hospitalized Subjects 2 to <12 Years Old
    Medical condition: Treatment or prophylaxis against Gram-positive infections
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10053021 Gram-positive bacterial infection LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA GB (Completed)
    Trial results: View results
    EudraCT Number: 2020-001102-29 Sponsor Protocol Number: 7100 Start Date*: 2020-07-03
    Sponsor Name:Department of Internal Medicine Vejle Hospital
    Full Title: Venetoclax and Dexamethasone in translocation (11;14) positive relapsed and refractory multiple myeloma (VICTORIA)
    Medical condition: Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 06 18:12:40 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA